comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists linked to lower risk for death, adverse CV GLP-1s Risk of major adverse cardiovascular
Description
G., Gratzl, S., et al
Rahmoune H, Thompson PW, Ward JM, et al
The demand is fueled by compelling demographic shifts
Injection site reactions are more common with amylin analogs, and the dual-mechanism approach means managing two sets of potential adverse effects
These medications replicate the activity of endogenous GLP-1, a hormone that is essential for glucose regulation
